Dr. Wendy Qiu, MD PhD

Claim this profile

Boston University

Studies Mild Cognitive Impairment
Studies Cognitive Impairment
2 reported clinical trials
2 drugs studied

Affiliated Hospitals

Image of trial facility.
Boston University
Image of trial facility.
BU Alzheimer Disease Center

Clinical Trials Wendy Qiu, MD PhD is currently running

Image of trial facility.

Diagnostic Test

for Alzheimer's Disease

In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. The investigative team has provided evidence in humans with full-blown AD and AD-relevant mouse models that a single injection of Pramlintide transiently renders the blood brain barrier (BBB) more permeable to Amyloidbeta (Aß) peptides, allowing their efflux from the brain compartment into the blood. This Aß efflux causes a corresponding transient elevation of blood levels of Aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by AV-45 PET. The measured difference in the level of plasma Aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood Aß levels. Supportive preliminary data comes from later stage (full-blown) AD patients with more in-depth background studies in Tg2576 and 5X Familial Alzheimer's Disease (FAD) mouse models. If successful for use as an early AD (i.e., at the Mild Cognitive Impairment \[MCI\] stage) biomarker, this could be a game-changer for both early AD diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of AD at early stages. If Pramlintide is effective in releasing mobile pools of Aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load. Three groups of particpants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints.
Recruiting1 award Phase < 1

More about Wendy Qiu, MD PhD

Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Wendy Qiu, MD PhD has experience with
  • Metformin
  • Pramlintide
Breakdown of trials Wendy Qiu, MD PhD has run

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wendy Qiu, MD PhD specialize in?
Wendy Qiu, MD PhD focuses on Mild Cognitive Impairment and Cognitive Impairment. In particular, much of their work with Mild Cognitive Impairment has involved treating patients, or patients who are undergoing treatment.
Is Wendy Qiu, MD PhD currently recruiting for clinical trials?
Yes, Wendy Qiu, MD PhD is currently recruiting for 1 clinical trial in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Wendy Qiu, MD PhD has studied deeply?
Yes, Wendy Qiu, MD PhD has studied treatments such as Metformin, Pramlintide.
What is the best way to schedule an appointment with Wendy Qiu, MD PhD?
Apply for one of the trials that Wendy Qiu, MD PhD is conducting.
What is the office address of Wendy Qiu, MD PhD?
The office of Wendy Qiu, MD PhD is located at: Boston University, Boston, Massachusetts 02118 United States. This is the address for their practice at the Boston University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.